EAST BRUNSWICK, N.J., May 29, 2009 (GLOBE NEWSWIRE) -- Savient Pharmaceuticals, Inc. (Nasdaq:SVNT) announced today that six abstracts (two oral presentations and four posters) about the Company’s product candidate KRYSTEXXA(tm) (pegloticase) will be presented at the European League Against Rheumatism (EULAR) 2009 Annual Congress June 10-13 in Copenhagen, Denmark addressing various aspects of treatment failure gout. Treatment failure gout occurs in patients with gout who have failed to normalize serum uric acid and whose signs and symptoms are inadequately controlled with urate-lowering therapy at the maximum medically appropriate dose or for whom those drugs are contraindicated.
